Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology ...

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with ...

A new research perspective was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 22 on December 18, 2024, entitled "Brown adipose ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced ...

Tension headaches can be a real pain, but there are several ways to relieve them at home. Here are our top tips to try and ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Our ...

In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically 'undruggable' protein, in just two months. This ...

Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

Our hypothesis is that BAT protects against impaired healthful longevity, i.e., obesity, diabetes, cardiovascular disorders, cancer, Alzheimer's ...